NeOnc Technologies Holdings, Inc. ( (NTHI) ) has provided an announcement.
On March 26, 2025, NeOnc Technologies Holdings, Inc. entered into securities purchase agreements with accredited investors to issue and sell common stock, raising approximately $1.6 million for working capital. The following day, the company announced a strategic partnership with CBCC Global Research to expand clinical trial capabilities in India, focusing on its neuro-oncology treatment. This collaboration will enable NeOnc to conduct trials across 30 FDA-compliant sites in India, accelerating patient enrollment and development efforts for its brain cancer therapies. The partnership signifies a critical step in NeOnc’s strategy to advance transformative treatments and improve patient outcomes globally.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a publicly traded clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics designed to overcome the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. NeOnc’s therapeutics are advancing under FDA Fast-Track and Investigational New Drug (IND) status.
YTD Price Performance: 10.32%
Average Trading Volume: 56,042
Find detailed analytics on NTHI stock on TipRanks’ Stock Analysis page.